Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 6/20 | 0.60 |
| ▸ | GFER | P55789 | 3/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16773340 | 0.82 | MAPT (0.61) | ALDH1A1HPGDATMMAPTGFER | |
| SCHEMBL14257096 | 0.81 | ALDH1A1 (0.61) | ALDH1A1HPGDATMMAPTGFER | |
| SCHEMBL29415390 | 0.76 | MAPT (1.00) | ALDH1A1HPGDATMMAPTGFER | |
| SCHEMBL29500467 | 0.76 | ALDH1A1 (0.59) | ALDH1A1HPGDATMMAPTGFER | |
| SCHEMBL13401778 | 0.76 | CYP2C19 (1.00) | ALDH1A1HPGDATMMAPTGFER | |
| SCHEMBL422634 | 0.75 | KDM4E (0.63) | ALDH1A1HPGDATMMAPTGFER | |
| SCHEMBL5367724 | 0.75 | KDM4E (0.63) | ALDH1A1HPGDATMMAPTGFER | |
| SCHEMBL9669552 | 0.74 | MAPT (0.62) | ALDH1A1HPGDATMMAPTGFER | |
| SCHEMBL2871452 | 0.73 | KDM4E (0.61) | ALDH1A1HPGDATMMAPTGFER | |
| SCHEMBL2871450 | 0.73 | KDM4E (0.61) | ALDH1A1HPGDATMMAPTGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353218-B2 | Kit for multifunctional compounds forming crosslinked biomaterials | ANGIOTECH PHARMACEUTICALS, INC. | 2016-05-31 | — | — | US | disclosed |
| US-9353218-B2 | Kit for multifunctional compounds forming crosslinked biomaterials | ANGIOTECH PHARMACEUTICALS, INC. | 2016-05-31 | — | — | US | disclosed |
| US-9326934-B2 | Drug delivery from rapid gelling polymer composition | ANGIOTECH INTERNATIONAL AG | 2016-05-03 | — | — | US | disclosed |
| US-9326934-B2 | Drug delivery from rapid gelling polymer composition | ANGIOTECH INTERNATIONAL AG | 2016-05-03 | — | — | US | disclosed |
| US-20150152114-A1 | PROCESS FOR THE PREPARATION OF AN INTERMEDIATE FOR A TRIAZOLOPYRIMIDINE CARBONUCLEOSIDE | ENANTIA, S.L. (ES) | 2015-06-04 | — | — | US | disclosed |
| US-20130289235-A1 | MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2013-10-31 | — | — | US | disclosed |
| US-20130289235-A1 | MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2013-10-31 | — | — | US | disclosed |
| US-8486437-B2 | Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use | ANGIOTECH PHARMACEUTICALS (US), INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8486437-B2 | Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use | ANGIOTECH PHARMACEUTICALS (US), INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8481073-B2 | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use | ANGIODEVICE INTERNATIONAL GMBH (CH) | 2013-07-09 | — | — | US | disclosed |
| US-8067031-B2 | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use | ANGIODEVICE INTERNATIONAL GMBH (CH) | 2011-11-29 | — | — | US | disclosed |
| US-8067031-B2 | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use | ANGIODEVICE INTERNATIONAL GMBH (CH) | 2011-11-29 | — | — | US | disclosed |
| US-20100092536-A1 | IMPLANTABLE SENSORS AND IMPLANTABLE PUMPS AND ANTI-SCARRING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2010-04-15 | — | — | US | disclosed |
| US-20100092536-A1 | IMPLANTABLE SENSORS AND IMPLANTABLE PUMPS AND ANTI-SCARRING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2010-04-15 | — | — | US | disclosed |
| US-20090214652-A1 | SOFT TISSUE IMPLANTS AND ANTI-SCARRING AGENTS | ANGIOTECH INTERNATIONAL AG (CH) | 2009-08-27 | — | — | US | disclosed |
| US-20090203632-A1 | COMPOSITIONS AND METHODS FOR TREATING CONTRACTURE | ANGIOTECH INTERNATIONAL AG (CH) | 2009-08-13 | — | — | US | disclosed |
| US-20090192214-A1 | DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION | ANGIOTECH INTERNATIONAL AG (CH) | 2009-07-30 | — | — | US | disclosed |
| US-20080312315-A1 | Multifunctional Compounds for Forming Crosslinked Biomaterials and Methods of Preparation and Use | ANGIOTECH PHARMACEUTICALS(US),INC. (US) | 2008-12-18 | — | — | US | disclosed |
| US-20080312315-A1 | Multifunctional Compounds for Forming Crosslinked Biomaterials and Methods of Preparation and Use | ANGIOTECH PHARMACEUTICALS(US),INC. (US) | 2008-12-18 | — | — | US | disclosed |
| US-20080058579-A1 | Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors | ANGIOTECH INTERNATIONAL AG (CH) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203632-A1 | COMPOSITIONS AND METHODS FOR TREATING CONTRACTURE | COL2A1, FN1, TNNC1 | ALDH1A1 3282/4885HPGD 629/4885ATM 2621/4885 |
| US-20150152114-A1 | PROCESS FOR THE PREPARATION OF AN INTERMEDIATE FOR A TRIAZOLOPYRIMIDINE CARBONUCLEOSIDE | NUDT1, DUT, UMPS | ALDH1A1 1625/4885HPGD 574/4885ATM 2922/4885 |
| US-20090214652-A1 | SOFT TISSUE IMPLANTS AND ANTI-SCARRING AGENTS | MMP1, COL2A1, FN1 | ALDH1A1 1677/4885HPGD 787/4885ATM 3124/4885 |
| US-20100092536-A1 | IMPLANTABLE SENSORS AND IMPLANTABLE PUMPS AND ANTI-SCARRING AGENTS | MMP1, CDKN1A, MKI67 | ALDH1A1 1386/4885HPGD 871/4885ATM 2501/4885 |
| US-20090192214-A1 | DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION | PGF, VCAM1, COL14A1 | ALDH1A1 1262/4885HPGD 543/4885ATM 2760/4885 |
| US-20080312315-A1 | Multifunctional Compounds for Forming Crosslinked Biomaterials and Methods of Preparation and Use | ILK, PLOD3, MMP1 | ALDH1A1 268/4885HPGD 628/4885ATM 1738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.